Following the news (Tuesday 17th July) that J&J’s HIV therapeutic, Symtuza, has been granted marketing approval by the FDA,
Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view:
“This news puts J&J’s Symtuza on track to launch in the US later this year, where it is predicted to be received well by physicians. Market forecasts predict a rapid uptake of Symtuza, allowing it to reach peak global sales of $860M in 2024.”
GlobalData’s report, ‘PharmaPoint: Human Immunodeficiency Virus (HIV)’ predicts that over 90% of these sales are expected to come from the US market, demonstrating the importance of this recent FDA approval for J&J’s Symtuza franchise.
“Symtuza is the only protease inhibitor-based single-tablet regimen (STR) containing J&J’s HIV monotherapy, Prezista. STR’s are associated with improved patient compliance compared with multi-tablet regimens, making Symtuza well positioned to seize some of the market share currently taken by multiple-pill combinations which include Prezista. This is expected to be the key driving factor for the uptake of this product across the global HIV market.
“Symtuza’s most significant competition in the HIV market is expected to come from other STRs. Gilead’s Biktarvy, which launched in the US earlier this year, is expected to dominate the HIV market for several years, and could stymie the overall sales potential of Symtuza. Furthermore, long-acting antiretroviral regimens are expected to launch in the HIV market in the near future, providing further competition to existing regimens due to the advantages which they provide with respect to patient compliance.”